Nonmalignant Adult Thoracic Lymphatic Disorders

Total Page:16

File Type:pdf, Size:1020Kb

Nonmalignant Adult Thoracic Lymphatic Disorders Nonmalignant Adult Thoracic Lymphatic Disorders Maxim Itkin, MD, FSIRa,*, Francis X. McCormack, MDb KEYWORDS Lymphangioma Lymphangiomatosis Lymphangiectasia Generalize lymphatic anomaly (GLA) Gorham-Stout disease (GSD) Kaposiform lymphangiomatosis (KL) Pulmonary lymphangiectasia Yellow nail syndrome KEY POINTS The thoracic lymphatic disorders typically present with symptoms of cough, shortness of breath, chyloptysis, or expectoration of branching casts. Typical pulmonary manifestations of the thoracic lymphatic disorders include chylous effusions, peribronchiolar interstitial infiltrates, and mediastinal masses. The emergence of sophisticated imaging techniques that characterize abnormal lymphatic flow promises to improve the classification and therapeutic approaches to the thoracic lymphatic disorders. INTRODUCTION conduits coursing on the surface of major airways in the hila and mediastinum and ultimately drain Primary lymphatic anomalies comprise a bewil- into the right lymphatic duct and thoracic duct dering array of congenital and acquired conditions (TD). The right lymphatic duct inserts into the sub- that can affect every organ system containing clavian vein in the neck and drains the right upper lymphatic channels, generally considered to be lobe. The TD inserts into the left innominate vein at all tissues except brain and bone marrow. the junction with the internal jugular vein and Lymphatic anomalies usually come to medical drains the left lung, right middle and lower lobes attention during childhood or early adulthood, of the right lung, as well as all structures below but can also present later in life. For the purpose the diaphragm (Fig. 1). A broad discussion of of this article, the discussion focuses on the lymphatic anatomy is beyond the scope of this lymphatic disorders that involve thoracic struc- article, but it is important to note that intestinal tures, either primarily or as part of a more global lymph (chyle) that contains chylomicrons (dietary lymphatic disease process, and which preferen- fats) enters the TD at the level of cisterna chyli in tially affect older children and adults. the upper abdomen and is transported to the The pulmonary lymphatics are a network of ves- venous system in the neck. The primary route thor- sels that function to transport cells and fluids from ough which chylous fluid reaches the pleural space the periphery of the lung to the central lymphatic or other thoracic structures in subjects with conduits, in order to regulate tissue pressure and chylous effusions, therefore, is either through (1) facilitate regional immune responses. The periph- reflux from an obstructed or pressure-overloaded eral lymphatic vessels converge on the larger Disclosures: None. a Interventional Radiology, Hospital of the University of Pennsylvania, Penn Medicine, 1 Silverstein, 3400 Spruce Street, Philadelphia, PA 19104, USA; b Division of Pulmonary, Critical Care and Sleep Medicine, Univer- sity of Cincinnati, MSB 6165, 231 Albert Sabin Way, Cincinnati, OH 45267-0564, USA * Corresponding author. E-mail address: [email protected] Clin Chest Med 37 (2016) 409–420 http://dx.doi.org/10.1016/j.ccm.2016.04.004 0272-5231/16/$ – see front matter Ó 2016 Elsevier Inc. All rights reserved. chestmed.theclinics.com 410 Itkin & McCormack Visceral pleura Contralateral Ipsilateral Visceral lymphatics course course pleura lymphatics Peribronchovascular lymphatic collectors Peribroncho- vascular lymphatic collectors Ipsilateral course Inferior Contralateral pulmonary course ligament Inferior pulmonary ligament Intra-abdominal Intra- collector abdominal collectors Visceral Visceral pleura pleura lymphatics lymphatics Arch of thoracic duct Right lymphatic Arch of collector arches thoracic duct Superior Left vena cava paratracheal collectors Right tracheobronchial node Right paratracheal Aortopulmonary collectors node Left tracheobronchial node Subcarinal node Fig. 1. Schematic representation of pulmonary lymphatic anatomy. (Adapted from Riquet M. Bronchial arteries and lymphatics of the lung. Thorac Surg Clin 2007;17:619–38; with permission.) TD into the pulmonary lymphatic stream, or (2) Extrapulmonary manifestations of the TLDs can through a pathologic connection between chylous include lymphatic leaks in various distributions lymphatics and the pleural space, airways, or lung (eg, chylous ascites), protein-losing enteropathy, parenchyma, as can occur following surgery or recurrent fevers and prostration, lymphatic trauma or as part of a pathologic process. Other obstruction resulting in lymphedema of extrem- thoracic chylous complications that can result ities, coagulopathy, and bony lesions. The TLDs from these 2 processes include chylous conges- often present in protean manner and can be tion in the lung parenchyma,1 plastic bronchitis congenital or acquired, localized or systemic. (PB; expectoration of branching casts),2 chyloper- Attempts to classify these disorders have gener- icardium, and chyloptysis. ally been based on defining commonalities of a The thoracic lymphatic disorders (TLD) limited number of cases or the consensus of comprise a group of diseases that are variably experts.3–6 Most of the published classification associated with mediastinal or pulmonary masses, systems use inconsistent terminology and lack interstitial infiltrates, airway disorders including clear diagnostic, clinical, laboratory, or imaging chyloptysis, PB, pleural effusions that are often standards. The TLDs are often grouped based on chylous, and repeated pulmonary infections and symptoms, age of presentation, histologic appear- bronchiectasis (eg, yellow nail syndrome, YNS). ance, associated illnesses, or secondary imaging Nonmalignant Adult Thoracic Lymphatic Disorders 411 findings rather than on unifying pathologic including lymphangioleiomyomatosis (LAM), or processes. YNS. The disorders we have chosen to discuss Common terms that have been used to describe below are a subset of TLDs that might conceivably primary lymphatic disorders include lymphan- present with pulmonary infiltrates, thoracic gioma, lymphangiectasia, lymphangiomatosis, masses, or chylous leaks in an adult pulmonary primary lymphedema,7 pulmonary lymphangiecta- clinic, including lymphangioma (a term that has sia (PL),8–10 intrathoracic lymphangiomatosis,11 now been replaced with microcystic or macrocys- thoracic lymphangiomatosis,12 diffuse pulmonary tic lymphatic malformation), diffuse pulmonary lymphangiomatosis,13 and mediastinal lymphan- lymphangiomatosis (DPL; a term that is obsolete giomatosis.14 The mode of clinical presentation is but without an accepted replacement, here called often added to modify these disease classifica- primary pulmonary lymphatic anomaly [PPLA]), tions, using terms idiopathic, congenital, neonatal, GLA with pulmonary involvement, a new subtype or acquired to describe chylothorax, chylous asci- of GLA called Kaposiform lymphangiomatosis tes, or chylopericardium.15–18 (KLA), lymphatic malformation in GSD, PB, and In particular, the terms lymphangioma and lym- YNS. Disorders that are exclusively found in neo- phangiectasia have been used interchangeably to nates primarily, are malignant, or which do not describe a heterogeneous group of disorders typically involve thorax, such as congenital chylo- associated with excess lymphatic tissue. Although thorax, primary lymphedema, Kaposi sarcoma, or both conditions are very similar histologically,6,19 lymphangiosarcoma, are not discussed in this by definition lymphangiomas are sequestered article. An overriding theme in this review is the from the main lymphatic system, and lymphan- importance of lymphatic imaging in classifying giectasias are connected to it. The primary means and treating these disorders. to differentiate between these 2 disorders clinically is with imaging capable of revealing lymphatic THORACIC LYMPHANGIOMAS (MICROCYSTIC flow. Revealing lymphatic flow was formerly AND MACROCYSTIC LYMPHATIC accomplished with pedal lymphangiogram and MALFORMATIONS) lymphoscintigraphy,20,21 which have been re- ported to demonstrate pathologic lymphatic flow Lymphangiomas are focal proliferations of well- (“lymphatic reflux”) in lymphangiectasia despite differentiated lymphatic tissue that present as its limitations in anatomic definition.22–24 Over the multicystic or sponge-like accumulations.19,28 In last few decades, however, these procedures many cases, they represent embryologic rem- have been less frequently performed and the nants of lymphatic tissues. Acquired or second- expertise required to execute them has been lost ary lymphangiomas can occur at the site of to many radiology departments. Intranodal radiation, trauma, or infection. Cystic lymphan- lymphangiogram (IL)25 and dynamic contrast- giomas (also known as cystic hygromas or cystic enhanced magnetic resonance lymphangiogram hydromas) can occur anywhere but are most (DCMRL)26,27 are new imaging techniques common in the armpit and the neck. In the that can better define lymphatic anatomy and thorax,theymanifestasmassesinthemedias- lymphatic flow. These approaches have tinum,29,30 pleura,31,32 or intrapulmonary33 distri- opened new vistas in the understanding the impor- butions (Fig. 2). Mediastinal lymphangiomas are tance of lymphatic flow in primary lymphatic equally distributed between the anterior, poste- disorders26,27 and will likely lead to more rational rior, and medial mediastinal compartments and approaches to classification. often envelop and displace mediastinal vessels. The International
Recommended publications
  • Nutritional Management of Chyle Leaks: an Update
    NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #94 Carol Rees Parrish, R.D., M.S., Series Editor Nutritional Management of Chyle Leaks: An Update Stacey McCray Carol Rees Parrish Chyle leaks are an uncommon but challenging complication for clinicians. Evidence- based guidelines for the management of chyle leaks are lacking. Nutrition therapy is a key component in the care of patients with chyle leaks and can range from primary treatment to adjunctive therapy. However, the best route for nutrition, the optimal mix of nutrients, and the required duration of the therapy are unclear. This article will review the options for a nutritional care plan and provide practical tips for imple- menting and monitoring such a plan. INTRODUCTION fat and fat-soluble vitamins. As the name implies, the he lymph system is a complex and integral network lymph system carries lymph, comprised of white blood of lymph vessels and organs throughout the body. cells (primarily lymphocytes) and chyle from the GI T The lymph system includes the lymph vessels and tract, throughout the body. Chyle (from the Latin word capillaries, the thoracic duct, lymph nodes, the spleen, for “juice”) contains fat, as well as protein, electrolytes, thymus, bone marrow and gut associated lymphoid tis- lymphocytes, and other substances. sue (GALT), as well as other structures. The primary The incidence of chyle leaks is low, however, when functions of the lymph system include its immunological they do occur, they can be difficult to manage and treat. role, the absorption of excess interstitial fluid and its A chyle leak may manifest in a variety of ways—as a chylothorax (chylous effusion) into the thoracic cavity, return to the bloodstream, and the transport of long chain as a chyloperitoneum (chylous ascites) into the Stacey McCray RD, Nutrition Support Specialist, abdomen, as a chylopericardium around the heart, or as Consultant and Carol Rees Parrish MS, RD, Nutrition an external draining fistula.
    [Show full text]
  • The Health-Related Quality of Life of Sarcoma Patients and Survivors In
    Cancers 2020, 12 S1 of S7 Supplementary Materials The Health-Related Quality of Life of Sarcoma Patients and Survivors in Germany—Cross-Sectional Results of A Nationwide Observational Study (PROSa) Martin Eichler, Leopold Hentschel, Stephan Richter, Peter Hohenberger, Bernd Kasper, Dimosthenis Andreou, Daniel Pink, Jens Jakob, Susanne Singer, Robert Grützmann, Stephen Fung, Eva Wardelmann, Karin Arndt, Vitali Heidt, Christine Hofbauer, Marius Fried, Verena I. Gaidzik, Karl Verpoort, Marit Ahrens, Jürgen Weitz, Klaus-Dieter Schaser, Martin Bornhäuser, Jochen Schmitt, Markus K. Schuler and the PROSa study group Includes Entities We included sarcomas according to the following WHO classification. - Fletcher CDM, World Health Organization, International Agency for Research on Cancer, editors. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press; 2013. 468 p. (World Health Organization classification of tumours). - Kurman RJ, International Agency for Research on Cancer, World Health Organization, editors. WHO classification of tumours of female reproductive organs. 4th ed. Lyon: International Agency for Research on Cancer; 2014. 307 p. (World Health Organization classification of tumours). - Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours. Eur Urol. 2016 Jul;70(1):106–19. - World Health Organization, Swerdlow SH, International Agency for Research on Cancer, editors. WHO classification of tumours of haematopoietic and lymphoid tissues: [... reflects the views of a working group that convened for an Editorial and Consensus Conference at the International Agency for Research on Cancer (IARC), Lyon, October 25 - 27, 2007]. 4. ed.
    [Show full text]
  • 1 the Physiological and Pathological Functions of VEGFR3 in Cardiac And
    Manuscript The physiological and pathological functions of VEGFR3 in cardiac and lymphatic development and related diseases Richard M. Monaghan, Donna J. Page, Pia Ostergaard and Bernard D. Keavney Downloaded from https://academic.oup.com/cardiovascres/advance-article/doi/10.1093/cvr/cvaa291/5926966 by guest on 21 October 2020 Abstract Vascular endothelial growth factor receptors (VEGFRs) are part of the evolutionarily conserved VEGF signalling pathways that regulate the development and maintenance of the body’s cardiovascular and lymphovascular systems. VEGFR3, encoded by the FLT4 gene, has an indispensable and well-characterised function in development and establishment of the lymphatic system. Autosomal dominant VEGFR3 mutations, that prevent the receptor functioning as a homodimer, cause one of the major forms of hereditary primary lymphoedema; Milroy disease. Recently, we and others have shown that FLT4 variants, distinct to those observed in Milroy disease cases, predispose individuals to Tetralogy of Fallot, the most common cyanotic congenital heart disease, demonstrating a novel function for VEGFR3 in early cardiac development. Here, we examine the familiar and emerging roles of VEGFR3 in the development of both lymphovascular and cardiovascular systems, respectively, compare how distinct genetic variants in FLT4 lead to two disparate human conditions, and highlight the research still required to fully understand this multifaceted receptor. key words: angiogenesis and lymphangiogenesis; primary lymphoedema; heart development; vascular endothelial growth factor receptors; congenital heart disease © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
    [Show full text]
  • The Nutrition and Food Web Archive Medical Terminology Book
    The Nutrition and Food Web Archive Medical Terminology Book www.nafwa.
    [Show full text]
  • About Soft Tissue Sarcoma Overview and Types
    cancer.org | 1.800.227.2345 About Soft Tissue Sarcoma Overview and Types If you've been diagnosed with soft tissue sarcoma or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Is a Soft Tissue Sarcoma? Research and Statistics See the latest estimates for new cases of soft tissue sarcoma and deaths in the US and what research is currently being done. ● Key Statistics for Soft Tissue Sarcomas ● What's New in Soft Tissue Sarcoma Research? What Is a Soft Tissue Sarcoma? Cancer starts when cells start to grow out of control. Cells in nearly any part of the body can become cancer and can spread to other areas. To learn more about how cancers start and spread, see What Is Cancer?1 There are many types of soft tissue tumors, and not all of them are cancerous. Many benign tumors are found in soft tissues. The word benign means they're not cancer. These tumors can't spread to other parts of the body. Some soft tissue tumors behave 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 in ways between a cancer and a non-cancer. These are called intermediate soft tissue tumors. When the word sarcoma is part of the name of a disease, it means the tumor is malignant (cancer).A sarcoma is a type of cancer that starts in tissues like bone or muscle. Bone and soft tissue sarcomas are the main types of sarcoma. Soft tissue sarcomas can develop in soft tissues like fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues.
    [Show full text]
  • A Case of Lymphangioleiomyomatosis Originated in the Pelvic Cavity
    J Gynecol Oncol Vol. 19, No. 3:195-198, September 2008 DOI:10.3802/jgo.2008.19.3.195 Case Report A case of lymphangioleiomyomatosis originated in the pelvic cavity Jung-Mi Han, Kyung-Hee Lee, Sung-Joo Kim, Chae-Chun Rhim, Young-Han Park, Jung-Bae Kang, Sun-Young Jeon1 Departments of Obstetrics and Gynecology, 1Pathology, Hallym University Medical College, Anyang, Korea Lymphangioleiomyomatosis is a rare disease that is characterized by proliferation of abnormal smooth muscle-like cells, especially that which occurs in the pulmonary parenchyme. It primarily affects women of child-bearing age. The majority of primary lymphangioleiomyomatosis occurs in the lung, but there are a few reports of extrapulmonary cases. We experienced a rare case of lymphangioleiomyomatosis which originated in the pelvic cavity (in the posterior portion of the uterus), and report with brief review of literatures. Key Words: Lymphangioleiomyomatosis, Pelvis, Uterus INTRODUCTION hypervascular tumor between the uterus and the right ovary, and two small myomas about 2 cm in size (Fig. 1). Under the Lymphangioleiomyomatosis is a very rare disease which impression of ovarian malignancy she had admitted for shows typical features of abnormal smooth muscle cell further evaluation including MRI. Her initial serum CA-125 proliferation and which develops in females during the level was 26.7 U/ml and CA 19-9 level was below 2 U/ml, and reproductive period.1,2 The majority cases of this disease other hematologic findings were all within the normal range. primarily occur in the lungs, but extrapulmonary regions such Magnetic resonance imaging study of the abdomen-pelvis as the pelvis and retroperitoneal spaces are occasionally demonstrated an approximately 4.0×5.0×4.0 cm sized tumor primary sites.
    [Show full text]
  • Brain-To-Cervical Lymph Node Signaling After Stroke
    ARTICLE https://doi.org/10.1038/s41467-019-13324-w OPEN Brain-to-cervical lymph node signaling after stroke Elga Esposito1, Bum Ju Ahn1, Jingfei Shi1,2, Yoshihiko Nakamura 1,3, Ji Hyun Park1, Emiri T. Mandeville 1, Zhanyang Yu1, Su Jing Chan 1,4, Rakhi Desai1, Ayumi Hayakawa1, Xunming Ji2, Eng H. Lo1,5*& Kazuhide Hayakawa1,5* After stroke, peripheral immune cells are activated and these systemic responses may amplify brain damage, but how the injured brain sends out signals to trigger systemic inflammation remains unclear. Here we show that a brain-to-cervical lymph node (CLN) 1234567890():,; pathway is involved. In rats subjected to focal cerebral ischemia, lymphatic endothelial cells proliferate and macrophages are rapidly activated in CLNs within 24 h, in part via VEGF-C/ VEGFR3 signalling. Microarray analyses of isolated lymphatic endothelium from CLNs of ischemic mice confirm the activation of transmembrane tyrosine kinase pathways. Blockade of VEGFR3 reduces lymphatic endothelial activation, decreases pro-inflammatory macro- phages, and reduces brain infarction. In vitro, VEGF-C/VEGFR3 signalling in lymphatic endothelial cells enhances inflammatory responses in co-cultured macrophages. Lastly, surgical removal of CLNs in mice significantly reduces infarction after focal cerebral ischemia. These findings suggest that modulating the brain-to-CLN pathway may offer therapeutic opportunities to ameliorate systemic inflammation and brain injury after stroke. 1 Neuroprotection Research Laboratory, Departments of Radiology and Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA. 2 China-America Institute of Neuroscience, Xuanwu Hospital, Capital Medical University, Beijing, China. 3 Department of Emergency and Critical Care Medicine, Fukuoka University Hospital, Jonan, Fukuoka, Japan.
    [Show full text]
  • Human Autoimmunity and Associated Diseases
    Human Autoimmunity and Associated Diseases Human Autoimmunity and Associated Diseases Edited by Kenan Demir and Selim Görgün Human Autoimmunity and Associated Diseases Edited by Kenan Demir and Selim Görgün This book first published 2021 Cambridge Scholars Publishing Lady Stephenson Library, Newcastle upon Tyne, NE6 2PA, UK British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library Copyright © 2021 by Kenan Demir and Selim Görgün and contributors All rights for this book reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the copyright owner. ISBN (10): 1-5275-6910-1 ISBN (13): 978-1-5275-6910-2 TABLE OF CONTENTS Preface ...................................................................................................... viii Chapter One ................................................................................................. 1 Introduction to the Immune System Kemal Bilgin Chapter Two .............................................................................................. 10 Immune System Embryology Rümeysa Göç Chapter Three ............................................................................................. 18 Immune System Histology Filiz Yılmaz Chapter Four .............................................................................................. 36 Tolerance Mechanisms and Autoimmunity
    [Show full text]
  • Lymphangioleiomyomatosis and Tuberous Sclerosis: Where Is the Border?
    Eur Respir J, 1996, 9, 399–401 Copyright ERS Journals Ltd 1996 DOI: 10.1183/09031936.96.09030399 European Respiratory Journal Printed in UK - all rights reserved ISSN 0903 - 1936 EDITORIAL Lymphangioleiomyomatosis and tuberous sclerosis: Where is the border? F. Bonetti*, P. Chiodera** Pulmonary lymphangioleiomyomatosis (PLAM) is a The key to addressing this unresolved question seems rare disease, characterized by an abnormal proliferation to be the definition of the diagnostic criteria of TS. The of smooth muscle throughout the lung; it occurs exclu- classical Vogt triad (seizures, mental retardation and facial sively in women, generally of reproductive age [1]. The angiofibroma) was the first important attempt to clini- muscle cells proliferating in PLAM show little or no cally define the syndrome. This diagnostic triad was atypia at histological level. Therefore, PLAM has been universally accepted and was, for a long time, consi- considered to be a hamartomatous lesion rather than a dered the hallmark of the disease. Whilst useful for clini- true neoplastic process. However, in spite of the bland cians, this approach led to a delay in the recognition of cytological features, the disease causes a progressive other diagnostic signs of TS, particularly the presence structural remodelling of the lung, leading to serious and classification of visceral lesions, such as angio- impairment of pulmonary function. Whilst survival curves myolipoma, so characteristic in this hereditary disease of now seem better than previously believed and hormonal autosomal dominant transmission. With the accumula- treatment has been introduced with encouraging results tion of knowledge on TS and the introduction of new [2], some patients progress to a condition necessitating diagnostic techniques, the Vogt triad has lost much of lung transplantation.
    [Show full text]
  • Differential Diagnostic Considerations
    Radiology Case Reports Volume 10, Issue 2, 2015 Chylothorax in a patient with metastatic Kaposi sarcoma: Differential diagnostic considerations Ryan Alexander, DO; Magda Rizer, DO; William Burke, MD; and Lawrence Ciment, MD Kaposi sarcoma (KS) is a low-grade mesenchymal tumor involving blood and lymphatic vessels. There are four types, based on clinical presentation: classic, endemic (Africana), iatrogenic (typically, involving renal allograft recipients), and AIDS-associated (epidemic). Kaposi’s sarcoma-associated herpes virus in- fection has been linked along with other factors to the development of KS. The Kaposi’s sarcoma- associated herpes virus interacts and encodes for numerous molecular proteins that play a role in the pathogenesis of KS, including latency-associated nuclear antigen, viral G protein-coupled receptor, viral FLICE inhibitory protein, and viral IL-6. KS primarily affects the skin and causes disseminated disease in a variety of organs. Involvement of visceral organs other than the lining of the alimentary tract is ex- tremely rare. While the chylous pleural effusions of KS may resemble other pulmonary diseases (includ- ing lymphangioma, lymphangectasis, and lymphangioleiomyomatosis) with chylous effusions at thoracic CT, differentiating features may allow for more prompt diagnosis and treatment. The presumptive diag- nosis of AIDS-related pulmonary KS is often clinical. A tissue diagnosis is not required to establish the diagnosis of pulmonary KS. There are a variety of causes of chylothorax. The primary finding is a near- water-attenuating pleural effusion. The secondary findings of chylothorax can help differentiate the etiology. Introduction be diagnosed on CT or MRI. The CT finding of chylous Chylothorax is a relatively uncommon cause of pleural effusions is typically a large unilateral effusion of water effusion (1).
    [Show full text]
  • Chyle Leak Post Laparoscopic Cholecystectomy: a Case Report, Literature Review and Management Options
    7 Case Report Page 1 of 7 Chyle leak post laparoscopic cholecystectomy: a case report, literature review and management options Ferdinand Ong1, Amitabha Das1, Kheman Rajkomar2 1Department of Upper Gastrointestinal Surgery, Liverpool Hospital, Sydney, NSW, Australia; 2Department of Upper Gastrointestinal Surgery, Bankstown-Lidcombe Hospital, Sydney, NSW, Australia Correspondence to: Dr. Kheman Rajkomar. Eldridge Road, Bankstown-Lidcombe Hospital, Bankstown NSW 2200, Sydney, Australia. Email: [email protected]. Abstract: Chyle leak after a laparoscopic cholecystectomy (LC) is very rarely reported. However, it is needs to be recognised promptly and managed as otherwise it can lead to further metabolic and infective complications. We present the case of a 48 years old man who was admitted with ultrasound proven acute calculous cholecystitis. His vital signs were within normal range but his murphy’s sign was positive. His white cell count (WCC) and liver function tests were within normal limit. He underwent an uneventful standard LC with cholangiography during the same admission with no anomalous biliary or hepatic arterial anatomy noted during the procedure. Post operatively he was noted to have 125 mL of white fluid in his drain. The fluid triglyceride was 23.2 mmol/L, cholesterol level was 2.8 mmol/L, and drain/serum triglyceride of 15.5, hence confirming it to be chyle. He was clinically otherwise very well. He was managed conservatively as a low volume chyle leak with a fat free diet. The triglyceride content in the drain effluent decreased to 1.3mmol/L by day 6 and the fluid turned straw coloured in that interval. The drain was removed and the patient discharged home without any further issues.
    [Show full text]
  • 2016 Essentials of Dermatopathology Slide Library Handout Book
    2016 Essentials of Dermatopathology Slide Library Handout Book April 8-10, 2016 JW Marriott Houston Downtown Houston, TX USA CASE #01 -- SLIDE #01 Diagnosis: Nodular fasciitis Case Summary: 12 year old male with a rapidly growing temple mass. Present for 4 weeks. Nodular fasciitis is a self-limited pseudosarcomatous proliferation that may cause clinical alarm due to its rapid growth. It is most common in young adults but occurs across a wide age range. This lesion is typically 3-5 cm and composed of bland fibroblasts and myofibroblasts without significant cytologic atypia arranged in a loose storiform pattern with areas of extravasated red blood cells. Mitoses may be numerous, but atypical mitotic figures are absent. Nodular fasciitis is a benign process, and recurrence is very rare (1%). Recent work has shown that the MYH9-USP6 gene fusion is present in approximately 90% of cases, and molecular techniques to show USP6 gene rearrangement may be a helpful ancillary tool in difficult cases or on small biopsy samples. Weiss SW, Goldblum JR. Enzinger and Weiss’s Soft Tissue Tumors, 5th edition. Mosby Elsevier. 2008. Erickson-Johnson MR, Chou MM, Evers BR, Roth CW, Seys AR, Jin L, Ye Y, Lau AW, Wang X, Oliveira AM. Nodular fasciitis: a novel model of transient neoplasia induced by MYH9-USP6 gene fusion. Lab Invest. 2011 Oct;91(10):1427-33. Amary MF, Ye H, Berisha F, Tirabosco R, Presneau N, Flanagan AM. Detection of USP6 gene rearrangement in nodular fasciitis: an important diagnostic tool. Virchows Arch. 2013 Jul;463(1):97-8. CONTRIBUTED BY KAREN FRITCHIE, MD 1 CASE #02 -- SLIDE #02 Diagnosis: Cellular fibrous histiocytoma Case Summary: 12 year old female with wrist mass.
    [Show full text]